Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Fluoguide AS
FLUOFluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. It has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; collaboration with Copenhagen University Hospital; collaboration with Intuitive Surgical, Inc. for robotics surgery in head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark. Address: Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Analytics
Precio Objetivo de WallStreet
1 481.27 SEKRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave FLUO
Análisis de dividendos FLUO
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout FLUO
Valoración de la acción FLUO
Finanzas FLUO
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |